Advanced search
Start date
Betweenand

Kinase prioritization and discovery of compounds with anti-malarial activity against different stages of Plasmodium vivax using chemogenomics, bioinformatics, cheminformatics, and experimental evaluation tools

Grant number: 19/21854-4
Support type:Scholarships in Brazil - Post-Doctorate
Effective date (Start): February 01, 2020
Effective date (End): January 31, 2022
Field of knowledge:Biological Sciences - Parasitology - Protozoology of Parasites
Principal Investigator:Fabio Trindade Maranhão Costa
Grantee:Joyce Villa Verde Bastos Borba
Home Institution: Instituto de Biologia (IB). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
Associated research grant:17/18611-7 - Development of new tools for search and validation of molecular targets for therapy against Plasmodium vivax, AP.TEM

Abstract

Malaria is one of the main diseases in tropical and subtropical countries in the world, caused by protozoa from the genus Plasmodium. Nowadays, the main strategy in the control of Malaria is based on the treatment. The always-recurrent resistance to the antimalarial drugs is a big barrier to the battle against Malaria, leading to new outbreaks of the disease. Among the potential new therapeutic targets against Malaria, the protein kinases stand out for their capabilities to interfere in other protein's activities through phosphorylation and for their involvement in almost all cellular processes. The kinome study is very important for the understanding of parasite physiology and gives information about how to interrupt adaptive mechanisms of these organisms. Computer-Aided Drug Design (CADD) is considered a great strategy to increase the success rate in the discovery of active compounds with a smaller cost. In this sense, the goal of this work plan is the identification of compounds that target kinases with antiplasmodial activity in P. vivax isolates through chemogenomics, bioinformatics, cheminformatics, and experimental assays strategies. To achieve this goal, we will characterize and update the kinome of different Plasmodium species, prioritize kinases as therapeutic targets and repurpose drugs that might target these kinases. We will also develop an integrative in silico platform to the discovery of new multistage antimalarial drugs. (AU)